Gueler A, Moser A, Calmy A, Gunthard HF, Bernasconi E, Furrer H, et al. Life expectancy
in HIV-positive persons in Switzerland: matched comparison with general population.
AIDS. 2017;31(3):427-36.
2.
Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults
on antiretroviral therapy across the globe: comparisons with general population. Curr
Opin HIV AIDS. 2016;11(5):492-500.
3.
Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, Sighem A, et al. Future challenges
for clinical care of an ageing population infected with HIV: a modelling study. Lancet
Infect Dis. 2015;15(7):810-8.
4.
World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral
drugs for treating and preventing HIV infection. 2016.
5.
Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, et al. Tenofovir use
is associated with a reduction in calculated glomerular filtration rates in the Swiss
HIV Cohort Study. Antivir Ther. 2007;12(8):1165-73.
6.
Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in
HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773-80.
7.
Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated
with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26(7):825-31.
8.
McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density
and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine
or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir:
Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-801.
9.
Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al.
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral
regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled,
multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43-52.
10.
Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, et al. Brief Report: Switching
to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine,
in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter,
Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2017;74(2):180-4.
11.
Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral
Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations
of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379-96.
12.
European AIDS Clinical Society (EACS). Guidelines for the treatment of HIV-positive
adults. October 2018 [Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.
13.
Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, Telenti A,
et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol. 2010;39(5):1179-89.
14.
Liverpool Drug Interaction Group UoL. Prescribing Resources: Interactions with NRTI
2018 [Available from: https://www.hiv-druginteractions.org/.
15.
Bickel M, Wyen C, Spinner C, Baumgarten A, editors. Switch from tenofovir disoproxil
fumarate (TDF)- to tenofovir alafenamide (TAF)-based regimens in clinical practice
- Real-world data of the German PROPHET cohort study. HIV Glasgow 2018.
16.
Elion R, Eron J, Santiago S, Sax P, editors. Clinical observations of antiretroviral
(ART) switching in HIV-suppressed patients after availability of TAF. HIV Glasgow
2018.
17.
Brown K, Sutherland G, O'Hara R, Bell D, editors. Real World Experience Using Tenofovir
Alafenamide Fumarate (TAF) in Glasgow, UK. HIV Glasgow 2018.
18.
Vergori A, Lorenzini P, Cozzi-Lepri A, Maggiolo F, editors. Incidence and determinants
of antiretroviral switching away from TDF-based backbone in the recent years in the
Icona Foundation Cohort. HIV Glasgow 2018.
19.
Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, et al. Switching to Tenofovir
Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected
Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label
Phase 3 Study. J Acquir Immune Defic Syndr. 2016;71(5):530-7.
20.
Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated
renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase
inhibitor-based therapy. J Infect Dis. 2008;197(1):102-8.
21.
Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil
fumarate: is there a true difference in efficacy and safety? J Virus Erad. 2018;4(2):72-9.
22.
Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, et al. Rifampicin
effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. The
Journal of antimicrobial chemotherapy. 2019:dkz068.